ASLN - ASLAN Pharmaceuticals Limited

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
5.32
-0.28 (-5.00%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous close5.60
Open5.58
Bid5.05 x 1100
Ask8.30 x 1000
Day's range5.32 - 5.59
52-week range5.00 - 10.44
Volume303
Avg. volume3,483
Market cap147.493M
Beta (3Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.31
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est11.75
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    ASLAN Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    SINGAPORE, Nov. 08, 2018 -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia.

  • GlobeNewswire12 days ago

    ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting

    SINGAPORE, Nov. 01, 2018 -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia.

  • GlobeNewswire15 days ago

    ASLAN Pharmaceuticals Appoints Robert E. Hoffman as Independent Director

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, announced today the appointment of Robert E. Hoffman as an Independent Non-Executive Director. Mr. Hoffman has more than 20 years of experience in leading and managing global biotechnology companies, and working with a number of public, late-stage oncology companies. In planned board changes following ASLAN’s listing on NASDAQ earlier this year, Professor Lai Mei-Shu and Dr. Jerome Shen, who served as Independent Non-Executive Director and Non-Executive Director respectively, will step down from ASLAN’s Board of Directors concurrently.

  • GlobeNewswire22 days ago

    New Data Presented on ASLAN’s varlitinib at ESMO Show Promising Results in Heavily Pre-Treated BTC and CRC Patients

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the presentation of new data from an ongoing phase 1 study to determine the safety, tolerability and maximum tolerated dose (MTD) of varlitinib in combination with oxaliplatin and capecitabine (COX) or oxaliplatin and 5-FU (FOL) in advanced solid tumours. The study findings, presented in a poster session today at the 2018 European Society for Medical Oncology (ESMO) Congress, indicate encouraging signs of efficacy for varlitinib as a treatment for late-stage oncology patients. The investigator-initiated trial was conducted by Dr Matthew Chau Hsien Ng and supported by ASLAN and the Singapore National Medical Research Council.

  • GlobeNewswire27 days ago

    ASLAN Pharmaceuticals Enrolls First Subject in Phase 1 Study for ASLAN004 in Atopic Dermatitis

    ASLAN Pharmaceuticals (ASLAN, 6497.TT, Nasdaq: ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the enrolment of the first subject in a phase 1 study investigating ASLAN004 as a therapeutic antibody for atopic dermatitis. The phase 1 trial is the first clinical study of ASLAN004 and will be conducted in Singapore, Australia and the United States.  The single ascending dose portion of the study will recruit healthy volunteers and the multiple ascending dose component will recruit moderate to severe atopic dermatitis patients. ASLAN004 is a fully human monoclonal antibody that targets the IL-13 receptor α1 subunit (IL-13Rα1) and has demonstrated inhibition of interleukin 4 (IL-4) and interleukin 13 (IL-13) in preclinical investigations.

  • GlobeNewswirelast month

    ASLAN Pharmaceuticals to Present Posters on Varlitinib and ASLAN003 at European Society for Medical Oncology Congress

    SINGAPORE, Oct. 09, 2018 -- ASLAN Pharmaceuticals (ASLAN, 6497.TT, Nasdaq: ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in.

  • GlobeNewswire2 months ago

    ASLAN Pharmaceuticals Presents Two Posters on Varlitinib at Chinese Society of Clinical Oncology Annual Meeting

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, announced today the presentation of two posters on varlitinib at the 21st Annual Meeting of Chinese Society of Clinical Oncology (CSCO) held in Xiamen, China, from 19 to 23 September 2018. Varlitinib is a potent, reversible, small molecule pan-HER inhibitor and is currently being developed by ASLAN across multiple indications including a global pivotal trial in biliary tract cancer and a global study in gastric cancer. Poster title: Multicenter Phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+ metastatic breast cancer (MBC) who failed prior trastuzumab therapy.

  • GlobeNewswire2 months ago

    ASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced an update to its planned timelines for the ongoing single-arm clinical trial in China testing varlitinib plus capecitabine in patients with advanced or metastatic biliary tract cancer (BTC). In the interim, ASLAN will continue to recruit patients into the study and provide a further update on study timelines in early 2019. ASLAN’s global pivotal study in second line BTC, TREETOPP, remains on track to complete patient enrolment in early 2019.

  • GlobeNewswire2 months ago

    ASLAN Pharmaceuticals to Present at HC Wainwright 20th Annual Global Investment Conference

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced its participation at the HC Wainwright 20th Annual Global Investment Conference. Dr Carl Firth, Chief Executive officer, is scheduled to present an overview of the company on Wednesday, 5 September 2018 at 10:00am ET. A live audio webcast of the presentation will be available via http://wsw.com/webcast/rrshq28/asln/ with an archived replay link available in the Investors section of ASLAN’s website at www.aslanpharma.com following the event.

  • GlobeNewswire3 months ago

    ASLAN Pharmaceuticals Granted Orphan Drug Designation by the FDA for ASLAN003 for the Treatment of Acute Myeloid Leukaemia

    ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that the US Food and Drug Administration (FDA) has granted ASLAN003 Orphan Drug Designation (ODD) as a treatment for acute myeloid leukaemia (AML). ASLAN003 is an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be first-in-class in AML. AML is a cancer of the myeloid line of blood cells, characterised primarily by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells.